<table border="1" frame="box" id="t52776324" rules="all" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 10. Drug Interactions: Pharmacokinetic Parameters for Lopinavir in the Presence of the Co-administered Drug for Recommended Alterations in Dose or Regimen </caption>
<tbody>
<tr valign="top">
<td stylecode="Toprule">
<content stylecode="bold">Co-administered Drug </content>
</td>
<td align="center" stylecode="Toprule">
<content stylecode="bold">Dose of Co-administered Drug <br/>    (mg)</content>
</td>
<td align="center" stylecode="Toprule">
<content stylecode="bold">Dose of KALETRA <br/>    (mg)</content>
</td>
<td align="center" stylecode="Toprule">
<content stylecode="bold">n</content>
</td>
<td align="center" colspan="3" stylecode="Toprule">
<content stylecode="bold">Ratio (in combination with Co-administered drug/alone) of Lopinavir Pharmacokinetic Parameters (90% CI); No Effect = 1.00 </content>
</td>
</tr>
<tr valign="top">
<td> </td>
<td> </td>
<td> </td>
<td align="center"> </td>
<td align="center">
<content stylecode="bold">C<sub>max</sub>
</content>
</td>
<td align="center">
<content stylecode="bold">AUC </content>
</td>
<td align="center">
<content stylecode="bold">C<sub>min</sub>
</content>
</td>
</tr>
<tr valign="top">
<td>Amprenavir</td>
<td align="center">750 twice daily, 10 d</td>
<td align="center">400/100 capsule twice daily, 21 d</td>
<td align="center">12</td>
<td align="center">0.72<br/>(0.65, 0.79) </td>
<td align="center">0.62<br/>(0.56, 0.70) </td>
<td align="center">0.43<br/>(0.34, 0.56) </td>
</tr>
<tr valign="top">
<td>Efavirenz<sup>1,2</sup>
</td>
<td align="center">600 at bedtime, 9 d </td>
<td align="center">400/100 capsule twice daily, 9 d</td>
<td align="center">11, 7*</td>
<td align="center">0.97<br/>(0.78, 1.22) </td>
<td align="center">0.81<br/>(0.64, 1.03) </td>
<td align="center">0.61<br/>(0.38, 0.97) </td>
</tr>
<tr valign="top">
<td> </td>
<td align="center">600 at bedtime, 9 d</td>
<td align="center">500/125 tablet <br/>twice daily, 10 d </td>
<td align="center">19</td>
<td align="center">1.12<br/>(1.02, 1.23) </td>
<td align="center">1.06<br/>(0.96, 1.17) </td>
<td align="center">0.90<br/>(0.78, 1.04) </td>
</tr>
<tr valign="top">
<td> </td>
<td align="center">600 at bedtime, 9 d</td>
<td align="center">600/150 tablet<br/>twice daily, 10 d </td>
<td align="center">23</td>
<td align="center">1.36<br/>(1.28, 1.44) </td>
<td align="center">1.36<br/>(1.28, 1.44) </td>
<td align="center">1.32<br/>(1.21, 1.44) </td>
</tr>
<tr valign="top">
<td>Fosamprenavir<sup>3</sup>
</td>
<td align="center">700 twice daily plus ritonavir 100 twice daily, 14 d</td>
<td align="center">400/100 capsule twice daily, 14 d</td>
<td align="center">18</td>
<td align="center">1.30<br/>(0.85, 1.47) </td>
<td align="center">1.37<br/>(0.80, 1.55) </td>
<td align="center">1.52<br/>(0.72, 1.82) </td>
</tr>
<tr valign="top">
<td>Ketoconazole</td>
<td align="center">200 single dose</td>
<td align="center">400/100 capsule twice daily, 16 d</td>
<td align="center">12</td>
<td align="center">0.89<br/>(0.80, 0.99) </td>
<td align="center">0.87<br/>(0.75, 1.00) </td>
<td align="center">0.75<br/>(0.55, 1.00) </td>
</tr>
<tr valign="top">
<td>Nelfinavir</td>
<td align="center">1000 twice daily, <br/>10 d </td>
<td align="center">400/100 capsule twice daily, 21 d</td>
<td align="center">13</td>
<td align="center">0.79<br/>    (0.70, 0.89) </td>
<td align="center">0.73<br/>    (0.63, 0.85) </td>
<td align="center">0.62<br/>    (0.49, 0.78) </td>
</tr>
<tr valign="top">
<td>Nevirapine</td>
<td align="center">200 twice daily, steady-state<br/>(&gt; 1 yr)<sup>4#</sup>
</td>
<td align="center">400/100 capsule twice daily,<br/>steady-state </td>
<td align="center">22, 19*</td>
<td align="center">0.81<br/>(0.62, 1.05) </td>
<td align="center">0.73<br/>(0.53, 0.98) </td>
<td align="center">0.49<br/>(0.28, 0.74) </td>
</tr>
<tr valign="top">
<td> </td>
<td align="center">7 mg/kg or 4 mg/kg once daily, 2 wk; twice daily 1 wk<sup>5</sup>
</td>
<td align="center">(&gt; 1 yr) 300/75 mg/m2<br/>oral solution<br/>twice daily, 3 wk </td>
<td align="center">12, 15*</td>
<td align="center">0.86<br/>(0.64, 1.16) </td>
<td align="center">0.78<br/>(0.56, 1.09) </td>
<td align="center">0.45<br/>(0.25, 0.81) </td>
</tr>
<tr valign="top">
<td>Omeprazole</td>
<td align="center">40 once daily, 5 d</td>
<td align="center">400/100 tablet twice daily, 10 d</td>
<td align="center">12</td>
<td align="center">1.08<br/>(0.99, 1.17) </td>
<td align="center">1.07<br/>(0.99, 1.15) </td>
<td align="center">1.03<br/>(0.90, 1.18) </td>
</tr>
<tr valign="top">
<td> </td>
<td align="center">40 once daily, 5 d</td>
<td align="center">800/200 tablet once daily, 10 d</td>
<td align="center">12</td>
<td align="center">0.94<br/>(0.88, 1.00) </td>
<td align="center">0.92<br/>(0.86, 0.99) </td>
<td align="center">0.71<br/>(0.57, 0.89) </td>
</tr>
<tr>
<td>Pitavastatin<sup>6</sup>
</td>
<td align="center" valign="top">4 mg once daily, 5 d</td>
<td>400/100 tablet twice daily, 16 d </td>
<td align="center" valign="top">23</td>
<td align="center" valign="top">0.93<br/>(0.88-0.98) </td>
<td align="center" valign="top">0.91<br/>(0.86-0.97)</td>
<td align="center" valign="top">NA</td>
</tr>
<tr valign="top">
<td>Pravastatin </td>
<td align="center">20 once daily, 4 d</td>
<td align="center">400/100 capsule twice daily, 14 d</td>
<td align="center">12</td>
<td align="center">0.98<br/>(0.89, 1.08) </td>
<td align="center">0.95<br/>(0.85, 1.05) </td>
<td align="center">0.88<br/>(0.77, 1.02) </td>
</tr>
<tr valign="top">
<td>Rifabutin</td>
<td align="center">150 once daily, 10 d</td>
<td align="center">400/100 capsule twice daily, 20 d</td>
<td align="center">14</td>
<td align="center">1.08<br/>(0.97, 1.19) </td>
<td align="center">1.17<br/>(1.04, 1.31) </td>
<td align="center">1.20<br/>(0.96, 1.65) </td>
</tr>
<tr valign="top">
<td>Ranitidine</td>
<td align="center">150 single dose</td>
<td align="center">400/100 tablet twice daily, 10 d</td>
<td align="center">12</td>
<td align="center">0.99<br/>(0.95, 1.03) </td>
<td align="center">0.97<br/>(0.93, 1.01) </td>
<td align="center">0.90<br/>(0.85, 0.95) </td>
</tr>
<tr valign="top">
<td> </td>
<td align="center">150 single dose</td>
<td align="center">800/200 tablet once daily, 10 d</td>
<td align="center">10</td>
<td align="center">0.97<br/>(0.95, 1.00) </td>
<td align="center">0.95<br/>(0.91, 0.99) </td>
<td align="center">0.82<br/>(0.74, 0.91) </td>
</tr>
<tr valign="top">
<td>Rifampin</td>
<td align="center">600 once daily,<br/>    10 d </td>
<td align="center">400/100 capsule twice daily, 20 d</td>
<td align="center">22</td>
<td align="center">0.45<br/>(0.40, 0.51) </td>
<td align="center">0.25<br/>(0.21, 0.29) </td>
<td align="center">0.01<br/>(0.01, 0.02) </td>
</tr>
<tr valign="top">
<td> </td>
<td align="center">600 once daily,<br/>    14 d </td>
<td align="center">800/200 capsule twice daily, 9 d<sup>7</sup>
</td>
<td align="center">10</td>
<td align="center">1.02<br/>(0.85, 1.23) </td>
<td align="center">0.84<br/>(0.64, 1.10) </td>
<td align="center">0.43<br/>(0.19, 0.96) </td>
</tr>
<tr valign="top">
<td> </td>
<td align="center">600 once daily,<br/>    14 d </td>
<td align="center">400/400 capsule twice daily, 9 d<sup>8</sup>
</td>
<td align="center">9</td>
<td align="center">0.93<br/>(0.81, 1.07) </td>
<td align="center">0.98<br/>(0.81, 1.17) </td>
<td align="center">1.03<br/>(0.68, 1.56) </td>
</tr>
<tr valign="top">
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td align="center" colspan="2">Co-administration of KALETRA and rifampin is contraindicated.<br/>    [see Contraindications (<linkhtml href="#section_4">4</linkhtml>)]</td>
</tr>
<tr valign="top">
<td>Ritonavir<sup>4</sup>
</td>
<td align="center">100 twice daily,<br/>    3-4 wk<sup>#</sup>
</td>
<td align="center">400/100 capsule twice daily,<br/>    3-4 wk </td>
<td align="center">8, 21*</td>
<td align="center">1.28<br/>    (0.94, 1.76) </td>
<td align="center">1.46<br/>    (1.04, 2.06) </td>
<td align="center">2.16<br/>    (1.29, 3.62) </td>
</tr>
<tr valign="top">
<td>Tenofovir<sup>9</sup>
</td>
<td align="center">300 mg once daily, <br/>    14 d </td>
<td align="center">400/100 capsule twice daily, 14 d</td>
<td align="center">24</td>
<td align="center">NC<sup>†</sup>
</td>
<td align="center">NC<sup>†</sup>
</td>
<td align="center">NC<sup>†</sup>
</td>
</tr>
<tr valign="top">
<td>Tipranavir/ritonavir<sup>4</sup>
</td>
<td align="center">500/200 mg twice daily (28 doses)<sup>#</sup>
</td>
<td align="center">400/100 capsule twice daily<br/>    (27 doses) </td>
<td align="center">21 <br/>    69 </td>
<td align="center">0.53<br/>    (0.40, 0.69)<sup>10</sup>
</td>
<td align="center">0.45<br/>    (0.32, 0.63)<sup>10</sup>
</td>
<td align="center">0.30 (0.17, 0.51)<sup>10</sup>
<br/>    0.48 (0.40, 0.58)<sup>11</sup>
</td>
</tr>
<tr>
<td colspan="7">All interaction studies conducted in healthy, HIV-1 negative subjects unless otherwise indicated.<br/> 1 The pharmacokinetics of ritonavir are unaffected by concurrent efavirenz.<br/>2 Reference for comparison is lopinavir/ritonavir 400/100 mg twice daily without efavirenz. <br/> 3 Data extracted from the fosamprenavir package insert.<br/> 4 Study conducted in HIV-1 positive adult subjects.<br/> 5 Study conducted in HIV-1 positive pediatric subjects ranging in age from 6 months to 12 years.<br/>6 Data extracted from the pitavastatin package insert and results presented at the 2011 International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (Morgan<content stylecode="italics">, et al, poster #MOPE170)</content>.<br/> 7 Titrated to 800/200 twice daily as 533/133 twice daily x 1 d, 667/167 twice daily x 1 d, then 800/200 twice daily x 7 d, compared to 400/100 twice daily x 10 days alone. <br/> 8 Titrated to 400/400 twice daily as 400/200 twice daily x 1 d, 400/300 twice daily x 1 d, then 400/400 twice daily x 7 d, compared to 400/100 twice daily x 10 days alone. <br/> 9 Data extracted from the tenofovir package insert.<br/> 10 Intensive PK analysis.<br/> 11 Drug levels obtained at 8-16 hrs post-dose.<br/> * Parallel group design; n for KALETRA + co-administered drug, n for KALETRA alone.<br/> † NC = No change.<br/> # For the nevirapine 200 mg twice daily study, ritonavir, and tipranavir/ritonavir studies, KALETRA was administered with or without food. For all other studies, KALETRA was administered with food. </td>
</tr>
</tbody>
</table>